- funded by IMI-JU
- 01 March 2011 - 31 August 2016
- 11 EFPIA members
- 10 Academia and 5 SME's
- Total cost € 23,032,609
Pfizer Inc. (Pfizer) is the world's largest research-based biomedical and pharmaceutical company. Pfizer has substantial experience in model based drug development, PK/PD modelling, pharmacometrics, systems biology methods within its integrated clinical pharmacology division. The clinical pharmacology group at Pfizer partners with development teams to bring new medicines to patients by providing R&D strategies throughout the whole development continuum.
Pfizer's pharmacometrics staff is responsible for the use of a variety of innovative quantitative methods to integrate disease models, pharmacokinetic data, response data (efficacy and safety), trial design and analytical techniques, determine and apply decision criteria in order to facilitate and improve quantitative decision making across the company.
Specific skills: Extensive experience across many modelling languages and use of these for a variety of modelling tasks. Experience at implementing PKPD modelling environment. Expertise in model-based drug development.
Kevin Sweeney Pfizer |
|
Lutz Harnisch Pfizer |
|
Mike Amantea Pfizer |
|
Mike K Smith Pfizer |
|
Peter Milligan Pfizer |
|
Phylinda Chan Pfizer |
|
Tom Tensfeldt Pfizer |
|
Vijay Sundararajan Pfizer |